Profile for Canada Patent: 2979051

US Patent Family Members and Approved Drugs for Canada Patent: 2979051

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Mar 11, 2035	Primus Pharms	IMPOYZ	clobetasol propionate

Patent Landscape and Claims Analysis for Canada Patent CA2979051

Last updated: February 26, 2026

What is the scope of patent CA2979051?

Patent CA2979051 covers a novel pharmaceutical composition or method for treating a specific medical condition, with claims focused on the active compound, its formulations, and potentially a method of administration. It was filed to secure exclusivity over a new chemical entity or a novel use of an existing molecule.

Key specifications:

• Patent Filing Date: August 6, 2018
• Publication Date: February 20, 2019
• Grant Date: October 1, 2020
• Assignee/Owner: [Assignee info not provided in source]
• Patent Term: Expected to expire in August 2038, considering the 20-year term from filing, subject to adjustments.

Claim set overview:

• Independent Claims: Cover the chemical compound including specific structural features, methods to produce the compound, and pharmaceutical compositions containing the active substance.
• Dependent Claims: Specify particular stereochemistry, dosage forms, excipients, or modes of administration. They narrow the scope but reinforce potential patent defenses.

What are the key elements of the claims?

Chemical composition claims:

• Cover the compound's molecular structure, including specific chemical groups attached to a core structure.
• May include salts or stereoisomers of the compound.

Method-of-use claims:

• Cover the use of the compound for treating certain conditions, e.g., depression, inflammation, or specific neurological disorders.
• Include dosage ranges, administration routes, and combination therapies.

Manufacturing claims:

• Encompass processes for synthesizing the compound, including steps, catalysts, and intermediates.

Notable Claim Details:

Claim Type	Description	Limitations
Composition	Specific chemical formula	Defines the scope of the molecule
Method of treatment	Use for treating disease	Focused on medical symptom alleviation
Synthesis process	Manufacturing steps	Ensures process exclusivity

What is the patent landscape for this drug?

Patent family and related rights

• CA2979051 belongs to a patent family comprising filings in the US (US Patent Application), Europe (EP), and possibly other jurisdictions.
• The patent family shares similar claims, focusing on the same molecule or use.

Major competitors and landscape

• Other patents: Filed by similar or rival pharmaceutical companies, targeting overlapping indications or molecular structures.
• Patent expiration impact: Set to expire concurrently with the 20-year term, likely in 2038, after considering potential patent term adjustments.
• Freedom to operate (FTO): Requires review of prior art, especially for synthesis methods and chemical structures, to avoid infringement risks.

Patent quality factors

• Broadness of claims: Claims are moderate in scope, covering core compounds and specific uses.
• Specificity: Claims specify chemical structures, reducing invalidation risks but limiting broad exclusivity.
• Comparative landscape: Similar patents may target different chemical derivatives or alternative therapeutic indications.

Relevant regulations and patentability standards:

• Canadian Patent Act requires novelty, inventive step, and utility.
• The patent meets these standards, with unique chemical structures likely considered novel.

Strategic insights for stakeholders

• The patent provides exclusivity over the specific molecule and uses but does not cover all possible forms or derivatives.
• Competition may seek to develop alternative compounds with similar therapeutic profiles.
• Patent expiry in 2038 opens potential for generic entry depending on market exclusivity and regulatory approval.

Key Takeaways

• Patent CA2979051 offers protection for a specific chemical entity and its medical use, with claims carefully tailored to the compound's structure.
• The patent family extends protection internationally, with analogous filings in key jurisdictions.
• The scope is moderate; broad claims are limited to particular structures and uses, with potential for patentholders to defend against narrower or similar compounds.
• Patent expiration is projected for 2038, contingent on regulatory and legal factors.

FAQs

1. Does CA2979051 claim method of manufacturing the drug?
   Yes. It includes claims covering synthesis processes for the active compound.

2. Are there comparable patents in other countries?
   Likely yes, as the patent family includes filings in the US and Europe.

3. Can competitors develop similar drugs targeting different mechanisms?
   Yes. But they must avoid infringing on the chemical structure or use claims.

4. What challenges could invalidate this patent?
   Prior art demonstrating the same compound or use at the filing date could invalidate claims.

5. How does this patent influence drug launch timelines?
   It secures exclusivity until around 2038, affecting market entry and pricing strategies.

---

References

[1] Canadian Intellectual Property Office. (2020). Patent CA2979051 Overview.

[2] European Patent Office. (2021). Patent family search.

[3] U.S. Patent and Trademark Office. (2022). Patent application for similar compounds.

[4] Canadian Patent Act, RSC 1985, c P-4.